Plant Name: Ilex kaushue
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.008E-15 | 1.961E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.143E-10 | 2.240E-06 | ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.779E-09 | 3.875E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.442E-09 | 5.765E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.894E-09 | 7.690E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.926E-09 | 8.378E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.057E-08 | 1.129E-05 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.917E-08 | 5.793E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.356E-06 | 8.438E-04 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 1.138E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.512E-06 | 1.436E-03 | CASP1, CASP7, MAPT, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.571E-06 | 1.436E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.066E-06 | 1.967E-03 | CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.892E-05 | 8.239E-03 | AKR1B1, AKR1B10, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.472E-10 | 7.510E-09 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.341E-08 | 5.680E-07 | CYP2C9; CDA; AKR1B10; CYP1A2; ALOX15; AKR1B1; TK1; CYP2C19; CYP3A4; XDH; PTGS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.352E-08 | 3.448E-07 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.563E-07 | 1.993E-06 | CYP2C9; CYP2D6; ALOX15; CYP2C19; PTGS1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.100E-07 | 2.142E-06 | CDA; TK1; CYP3A4; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.092E-07 | 6.028E-06 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.372E-06 | 9.997E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.190E-06 | 1.396E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.539E-05 | 2.825E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.876E-03 | 5.893E-03 | TSHR; PTGS1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.810E-03 | 5.893E-03 | CASP7; CASP1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.080E-03 | 5.893E-03 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 7.783E-04 | 2.835E-03 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.396E-04 | 2.293E-03 | AKR1B10; AKR1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.011E-03 | 5.893E-03 | CYP1A2; CYP3A4 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.144E-04 | 2.410E-03 | AKR1B10; AKR1B1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.336E-03 | 8.954E-03 | CASP7; CASP1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.118E-02 | 2.715E-02 | CASP7; LMNA |
| hsa00240 | Pyrimidine metabolism_Homo sapiens_hsa00240 | 6.428E-03 | 1.639E-02 | CDA; TK1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.581E-02 | 3.664E-02 | CASP7; MAPT |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.703E-04 | 7.893E-04 | CA12; CA9 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.262E-05 | 7.154E-05 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Prostate cancer | C61 | TK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA9; TK1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; TK1; CDA |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |